Cambridge Cancer Genomics (CCG) is a Y Combinator backed healthtech startup building tools to enable oncologists to make the best therapeutic decisions for their patients.

The Problem

Most drugs don't work for every tumor. And it takes too long to figure that out.

First line chemotherapy fails for 2 out of every 3 patients with certain cancer types.

Targeted therapies and immunotherapies fail for 1 out of every 3 patients.

Scans can be as infrequent as once every 6 months. Patients are left on ineffective therapies, with all the associated side-effects, for too long. 

The Solution

Precision Oncology: personalize treatments to the individual.

CCG deeply profiles a tumor's biology by DNA and RNA sequencing. We use machine learning and big data analytics to understand what this data means for individual clinical response.

CCG integrates genomic information with EMR data to infer suitable clinical trials or FDA approved drugs. We use machine learning to predict which drugs are likely to be effective.

CCG periodically measures treatment response from low-invasive blood draws. We make sure that the medications predicted to work are indeed working on an individual level.